JPH06509549A - ナブメトン粉末剤 - Google Patents

ナブメトン粉末剤

Info

Publication number
JPH06509549A
JPH06509549A JP4507661A JP50766192A JPH06509549A JP H06509549 A JPH06509549 A JP H06509549A JP 4507661 A JP4507661 A JP 4507661A JP 50766192 A JP50766192 A JP 50766192A JP H06509549 A JPH06509549 A JP H06509549A
Authority
JP
Japan
Prior art keywords
nabumetone
powder formulation
powder
inflammatory
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP4507661A
Other languages
English (en)
Japanese (ja)
Inventor
オルダニ，ディエゴ
フランチェーゼ，フランコ
ベルチェジ，ジャン・ピエロ
Original Assignee
スミスクライン・ビーチャム・ファーマシューティチ・ソシエタ・ペル・アチオニ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by スミスクライン・ビーチャム・ファーマシューティチ・ソシエタ・ペル・アチオニ filed Critical スミスクライン・ビーチャム・ファーマシューティチ・ソシエタ・ペル・アチオニ
Publication of JPH06509549A publication Critical patent/JPH06509549A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP4507661A 1991-04-15 1992-04-10 ナブメトン粉末剤 Pending JPH06509549A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9108128,1 1991-04-15
GB919108128A GB9108128D0 (en) 1991-04-15 1991-04-15 Novel formulation
PCT/EP1992/000839 WO1992018114A1 (en) 1991-04-15 1992-04-10 Nabumetone powders

Publications (1)

Publication Number Publication Date
JPH06509549A true JPH06509549A (ja) 1994-10-27

Family

ID=10693399

Family Applications (1)

Application Number Title Priority Date Filing Date
JP4507661A Pending JPH06509549A (ja) 1991-04-15 1992-04-10 ナブメトン粉末剤

Country Status (10)

Country Link
EP (1) EP0580658A1 (pt)
JP (1) JPH06509549A (pt)
BR (1) BR9205848A (pt)
CA (1) CA2108379A1 (pt)
GB (1) GB9108128D0 (pt)
IE (1) IE921194A1 (pt)
MX (1) MX9201735A (pt)
PT (1) PT100380A (pt)
WO (1) WO1992018114A1 (pt)
ZA (1) ZA922685B (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7205701A (en) * 2000-02-08 2001-08-20 Smithkline Beecham Corporation Method and compositions for treating an inflammatory disease

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1474377A (en) * 1973-09-11 1977-05-25 Beecham Group Ltd Naphthalene derivatives
GB8416638D0 (en) * 1984-06-29 1984-08-01 Beecham Group Plc Topical treatment and composition
GB8909793D0 (en) * 1989-04-28 1989-06-14 Beecham Group Plc Pharmaceutical formulation

Also Published As

Publication number Publication date
WO1992018114A1 (en) 1992-10-29
GB9108128D0 (en) 1991-06-05
CA2108379A1 (en) 1992-10-16
IE921194A1 (en) 1992-10-21
BR9205848A (pt) 1994-11-08
EP0580658A1 (en) 1994-02-02
ZA922685B (en) 1993-02-24
PT100380A (pt) 1993-06-30
MX9201735A (es) 1992-10-01

Similar Documents

Publication Publication Date Title
US4556678A (en) Sustained release propranolol tablet
KR20020050249A (ko) 포스포디에스테라제 4 억제제의 투여 방법
Koren et al. Difficulty in achieving therapeutic serum concentrations of salicylate in Kawasaki disease
US20240100020A1 (en) Medicine for relieving or eliminating protracted opioid abstinence syndrome and preparation method therefor
JPH08291077A (ja) 骨萎縮改善剤
JPH06509549A (ja) ナブメトン粉末剤
JPS60215635A (ja) アザプロパゾンを含有する医薬品製剤
JPS61251622A (ja) 胃粘膜　細胞を保護するアスピリン含有組成物
Olive et al. Effect of age and disease on the pharmacokinetics of nimesulide
Bayer et al. Bioavailability and acceptability of a dispersible formulation of levodopa‐benserazide in parkinsonian patients with and without dysphagia
KR100697093B1 (ko) 비타민 ｃ 및 감기 치료제를 함유하는 이중정 제형 및 그의제조방법
CN114007616A (zh) (s)-3-氨基-6-甲氧基-n-(3，3，3-三氟-2-羟基-2-甲基丙基)-5-(三氟甲基)吡啶甲酰胺的配制品
JP4710240B2 (ja) 医薬組成物
JP2003095981A (ja) 医薬組成物
Madathil et al. Formulation and evaluation of fast dissolving tablets of trimetazidine dihydrochloride using natural and synthetic superdisintegrants
US7199153B2 (en) Pharmaceutical composition comprising paracetamol and niflumic acid
US11801236B2 (en) Pramipexole hydrochloride oral liquid
Orton et al. Plasma salicylate levels after soluble and effervescent aspirin.
Laroudie et al. Pharmacokinetic evaluation of co-administration of nefazodone and lithium in healthy subjects
JP2005289905A (ja) 医薬組成物
JP2000229853A (ja) 生理痛改善用組成物
EP0230125A1 (en) Admixtures of diflunisal and tromethamine
EP2848259B1 (en) Sustained release pharmaceutical formulations of Thiocolchicoside
KR100904165B1 (ko) 아세트아미노펜 현탁정 및 그의 제조방법
JPH0959149A (ja) 消炎鎮痛組成物